Boston Scientific scores CE mark for new defibrillator system; Cynosure settles patent suit;

@FierceMedDev: TruTouch Technologies (biometric alcohol sensor) names Marathon's Bruce Berger CEO. Release | Follow @FierceMedDev

@MarkHFierce: In an interesting twist, ViewRay's new $30M round includes an investment from a Chinese distributor. Story | Follow @MarkHFierce

@MichaelGFierce: Alnylam begins PhII trial for amyloidosis RNAi treatment. Item from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: Boston Scientific recruits a veteran Silicon Valley investor amid its M&A push. More | Follow @GalenMoore

> Boston Scientific ($BSX) gained a CE mark for its new X4 line of quadripolar cardiac resynchronization therapy defibrillators, plus a new line of leads and a lead delivery system. Item

> Navidea Biopharmaceuticals has submitted a supplemental new drug application to the FDA to use its Lymphoseek injectable agent to map the spread of tumors in patients with head and neck cancer. It is currently approved to do the same for breast cancer and melanoma. Item

> Cosmetic laser manufacturer Cynosure ($CYNO) has settled a patent lawsuit against Tria Beauty for $10 million. Story

> Medicare has identified the 97 best and 95 worst hospitals for hip and knee replacements. Story

> Ireland's Health Services (HSE), rather than the Health Department, will pay for the removal of leaking breast implants stemming from last year's PIP scandal, but patients will still have to pay for replacement implants. Story

Biotech News

@FierceBiotech: Biogen Idec preps for a big leap into the anti-TNF blockbuster biosimilars market. More | Follow @FierceBiotech

@JohnCFierce: "Amy Schulman and Pfizer have agreed to separate." What, no retirement? More | Follow @JohnCFierce

@DamianFierce:  Amgen keeps with the PCSK9 pack in its first Phase III results for evolocumab. News | Follow @DamianFierce

@EmilyMFierce: Researchers find a possible drug target for undruggable melanoma. Story | Follow @EmilyMFierce

> Organogenesis slashes its R&D staff as Medicare preps a big price cut. More

> Imperial spearheads $28M round for an upstart in the antibody fragment field. Article

Pharma News

@FiercePharma: Whoa: Amy Schulman is out, rather abruptly, at Pfizer. She was one of the three division chiefs chosen by CEO Ian Read earlier this year. | Follow @FiercePharma

@EricPFierce: Teva renegs on plans to build a new API plant in India. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Pfizer names Albert Bourla Group President; Vaccines, Oncology and Consumer Healthcare Business. Release | Follow @CarlyHFierce

> Almirall eyes growth in U.S., dermatology with $400M Aqua Pharma buyout. Story

> Traders bet Novartis CEO will bail out of its $14B Roche stake. More

> Amy Schulman, tapped to lead a new Pfizer division, makes an abrupt exit. News

> GlaxoSmithKline scraps doc payments, sales-rep quotas in global marketing revamp. Article

> Supreme Court won't take up ex-InterMune CEO's free-speech defense. Report

> Chinese whistleblower tags Shanghai Pharma with bribery allegations. Item

Pharma Manufacturing News

> China rounds up hundreds in crackdown against drug counterfeiters. More

> Novartis' OTC recall is tied to a contractor this time. Story

> Novartis to shed Alcon plant, 300 jobs next year. News

> What's a makeover cost these days? For AstraZeneca's distribution hub, $100M. Article

> Teva reneges on its proposal to build a $141M API plant in India. Report

> Wales fines companies £120,000 for worker accidents. Item

Biotech Research News

> Congressional budget deal would ease NIH sequester cuts. Story

> Report: Life science research needs standards to curb irreproducible studies. More

> CIRM awards $61M for cancer research. Item

> Researchers find possible drug targets for undruggable melanomas. News

> Blood vessel breakdown in the brain may be linked to Alzheimer's. Report

Glaxo compound slows Lou Gehrig's disease in animal models. Article

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.